Plus Therapeutics CMO Dr. Norman LaFrance resigns effective June 12, 2024

PLUS THERAPEUTICS, INC.

Dr. Norman LaFrance resigned as Chief Medical Officer on June 5, 2024.
Resignation effective June 12, 2024; no reason provided in the filing.
No successor or interim CMO announced; President & CEO Marc Hedrick signs 8-K.
Company trades on Nasdaq under ticker PSTV.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Norman LaFrance

Chief Medical Officer

PSTV · PLUS THERAPEUTICS, INC.

Effective: 2024-06-12
Filed: June 7, 2024, 7:59 PM ET

On June 5, 2024, Plus Therapeutics, Inc. (the “Company”) received the resignation of Dr. Norman LaFrance, its Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Norman LaFrance resigned as Chief Medical Officer at PLUS THERAPEUTICS, INC..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On June 5, 2024, Plus Therapeutics, Inc. (the “Company”) received the resignation of Dr. Norman LaFrance, its Chief Medical Officer.

View on SEC.gov

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-070569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.